News | November 20, 2014

Oxford University Study at AHA Shows Extent of Vascular Damage Caused by Smoking

The researchers found that smokers were 12 times more likely than non-smokers to develop an abdominal aortic aneurism

Oxford clinical study, American Heart Association, abdominal aortic aneurism

Photo courtesy of Portable Networks Graphics


November 20, 2014 — Oxford University researchers presented data that reveal the extent to which smoking causes silent but deadly damage to health at the annual scientific meeting of the American Heart Association (AHA).

Working with Life Line Screening’s database of several million U.S. adults, Oxford researchers looked at people without symptoms who attended the company’s screening service. The researchers found that smokers were 12 times more likely than non-smokers to develop an abdominal aortic aneurism.

They also found that rates of aortic aneurysms were 12 times higher, leg circulation problems seven times higher and carotid artery narrowing five times higher in current smokers compared to those who have never smoked. 

“Smokers are much more likely to develop life-threatening vascular problems,” said Richard Bulbulia, M.D., who led the study.

The researchers used screening data from 3.1 million U.S. adults who underwent four non-invasive procedures: ultrasound of the carotid artery, ultrasound of the aorta, an ECG to help determine stroke risk and blood pressure in the arms and legs to assess circulation. The results are being presented today at the AHA Annual Meeting in Chicago and show the importance of cigarette smoking as a risk factor for these asymptomatic, silent conditions.

The work will also help determine the importance of high cholesterol, high blood pressure and obesity for these ‘silent’ vascular conditions, helping to prevent significant disease and premature death from vascular disease.

This work is funded by a Henry Goodger Fellowship, and CTSU receives core funding from the British Heart Foundation, UK Medical Research Council and Cancer Research UK.

For more information: www.ctsu.ox.ac.uk


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now